GlassScriptPhysician profile
Andrew O Lewicky
NPI 1407893449
$1,369.60
in general payments reported to CMS, 2019-2025
18 companies · $135 in 2025
The $135 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $77.81 · 2020: $88.91 · 2021: $337 · 2022: $173 · 2023: $218 · 2024: $339 · 2025: $135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $693.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $692.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $280.65 | 2021-2025 | Rocklatan |
| Abbvie INC. | $234.02 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $210.54 | 2019-2023 | |
| Aerie Pharmaceuticals, INC. | $183.02 | 2020-2021 | |
| Mallinckrodt Hospital Products INC. | $96.06 | 2023-2024 | Acthar |
| Rxsight INC | $86.51 | 2023 | Rxsight Light Adjustable Lens (Rxlal), Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Coherus Oncology, INC. | $38.90 | 2023 | |
| Biotissue Holdings INC. | $35.12 | 2021-2024 | |
| Ani Pharmaceuticals, INC. | $30.36 | 2025 | Purified Cortrophin Gel |
| Beaver-Visitec International, INC. | $28.98 | 2024 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $24.66 | 2020 | |
| Tarsus Pharmaceuticals, INC. | $22.27 | 2024 | Xdemvy |
| Thea Pharma INC. | $20.04 | 2024 | Iyuzeh |
| Shire North American Group INC | $19.58 | 2019 | |
| Astellas Pharma US INC | $19.17 | 2025 | Izervay |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| New World Medical,INC. | $14.57 | 2019 | |
| Apellis Pharmaceuticals, INC. | $13.09 | 2023 | Syfovre |
| Lupin INC. | $12.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Lewicky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.